| Pan-cancer analysis of advanced patient tumors reveals interactions between therapy and genomic landscapes E Pleasance, E Titmuss, L Williamson, H Kwan, L Culibrk, EY Zhao, ... Nature Cancer 1 (4), 452-468, 2020 | 127 | 2020 |
| Identification and analyses of extra-cranial and cranial rhabdoid tumor molecular subgroups reveal tumors with cytotoxic T cell infiltration HJE Chun, PD Johann, K Milne, M Zapatka, A Buellesbach, N Ishaque, ... Cell reports 29 (8), 2338-2354. e7, 2019 | 84 | 2019 |
| Genome and transcriptome biomarkers of response to immune checkpoint inhibitors in advanced solid tumors A Pender, E Titmuss, ED Pleasance, KY Fan, H Pearson, SD Brown, ... Clinical Cancer Research 27 (1), 202-212, 2021 | 65 | 2021 |
| Whole-genome and transcriptome analysis enhances precision cancer treatment options E Pleasance, A Bohm, LM Williamson, JMT Nelson, Y Shen, M Bonakdar, ... Annals of Oncology 33 (9), 939-949, 2022 | 63 | 2022 |
| Analysis of Ugandan cervical carcinomas identifies human papillomavirus clade–specific epigenome and transcriptome landscapes A Gagliardi, VL Porter, Z Zong, R Bowlby, E Titmuss, C Namirembe, ... Nature genetics 52 (8), 800-810, 2020 | 48 | 2020 |
| Clinical response to nivolumab in an INI1-deficient pediatric chordoma correlates with immunogenic recognition of brachyury LM Williamson, CM Rive, D Di Francesco, E Titmuss, HJE Chun, ... NPJ Precision Oncology 5 (1), 103, 2021 | 26 | 2021 |
| Integrative analysis of KRAS wildtype metastatic pancreatic ductal adenocarcinoma reveals mutation and expression-based similarities to cholangiocarcinoma JT Topham, ES Tsang, JM Karasinska, A Metcalfe, H Ali, SE Kalloger, ... Nature Communications 13 (1), 5941, 2022 | 17 | 2022 |
| Clinical and cost outcomes following genomics‐informed treatment for advanced cancers D Weymann, S Pollard, B Chan, E Titmuss, A Bohm, J Laskin, SJM Jones, ... Cancer Medicine 10 (15), 5131-5140, 2021 | 14 | 2021 |
| Therapeutic implication of genomic landscape of adult metastatic sarcoma X Feng, E Pleasance, EY Zhao, T Ng, JK Grewal, N Mohammad, ... JCO precision oncology 3, 1-25, 2019 | 14 | 2019 |
| Endogenous retrovirus transcript levels are associated with immunogenic signatures in multiple metastatic cancer types JT Topham, E Titmuss, ED Pleasance, LM Williamson, JM Karasinska, ... Molecular cancer therapeutics 19 (9), 1889-1897, 2020 | 12 | 2020 |
| Liver Metastases and Immune Checkpoint Inhibitor Efficacy in Patients with Refractory Metastatic Colorectal Cancer: A Secondary Analysis of a Randomized Clinical Trial EX Chen, JM Loree, E Titmuss, DJ Jonker, HF Kennecke, S Berry, ... JAMA Network Open 6 (12), e2346094-e2346094, 2023 | 11 | 2023 |
| Rearrangement-mediated cis-regulatory alterations in advanced patient tumors reveal interactions with therapy Y Zhang, F Chen, E Pleasance, L Williamson, CJ Grisdale, E Titmuss, ... Cell reports 37 (7), 2021 | 9 | 2021 |
| Homologous recombination deficiency signatures in gastrointestinal and thoracic cancers correlate with platinum therapy duration ES Tsang, V Csizmok, LM Williamson, E Pleasance, JT Topham, ... NPJ Precision Oncology 7 (1), 31, 2023 | 8 | 2023 |
| Establishing a framework for the clinical translation of germline findings in precision oncology K Dixon, S Young, Y Shen, ML Thibodeau, A Fok, E Pleasance, E Zhao, ... JNCI Cancer Spectrum 4 (5), pkaa045, 2020 | 7 | 2020 |
| TMBur: a distributable tumor mutation burden approach for whole genome sequencing E Titmuss, RD Corbett, S Davidson, S Abbasi, LM Williamson, ... BMC Medical Genomics 15 (1), 190, 2022 | 6 | 2022 |
| Comprehensive transcriptome analysis reveals link between epigenetic dysregulation, endogenous retrovirus expression and immunogenicity in metastatic colorectal carcinoma. SR Mendis, JT Topham, E Titmuss, L Williamson, ED Pleasance, ... Journal of Clinical Oncology 37 (15_suppl), 3535-3535, 2019 | 4 | 2019 |
| Chemokine expression predicts T cell-inflammation and improved survival with checkpoint inhibition across solid cancers JM Romero, E Titmuss, Y Wang, J Vafiadis, A Pacis, GH Jang, A Zhang, ... NPJ Precision Oncology 7 (1), 73, 2023 | 3 | 2023 |
| Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis SY Irene, K Wee, L Williamson, E Titmuss, J An, S Naderi-Azad, C Metcalf, ... Melanoma research 32 (4), 278-285, 2022 | 2 | 2022 |
| Immune activation following Irbesartan treatment in a colorectal cancer patient: a case study E Titmuss, K Milne, MR Jones, T Ng, JT Topham, SD Brown, DF Schaeffer, ... International Journal of Molecular Sciences 24 (6), 5869, 2023 | 1 | 2023 |
| Assessment of a 4-chemokine signature in prediction of T-cell inflammation and response to immune checkpoint inhibition across tumor types. JM Romero, E Titmuss, Y Wang, J Vafiadis, A Pacis, GH Jang, A Zhang, ... Journal of Clinical Oncology 40 (16_suppl), 2558-2558, 2022 | 1 | 2022 |
Daniel RenoufBC Cancer Agency在 bccancer.bc.ca 的电子邮件经过验证
